Beursonline.nl

[verwijderd] 3 november 2006 15:27

0

Duizenden berichten in één thread zorgt niet bepaald voor duidelijkheid. Daarom zetten we threads die meer dan 1.000 berichten hebben voort in een nieuwe thread: deel 2.

--- Vorige delen ---
Deel 1: www.iex.nl/forum/topic.asp?forum=228&...

--- Website bedrijf ---
www.crucell.com

--- Koersen ---
www.iex.nl/stocks/stocks_detail.asp?I...

--- Informatie toevoegen? ---
Om deze startpost uitgebreider te maken kunnen jullie concrete info/links mailen naar forum@iex.nl. Wij zullen deze informatie, mits geschikt, toevoegen aan deze startpost!

Met vriendelijke groet,

Eric Mencke
forum@iex.nl

[verwijderd] 4 november 2006 13:13

0

NRC zaterdag

Vogelgriep-vaccins zijn matig
Door onze redactie wetenschap
rotterdam, 4 nov. De resultaten van studies met vrijwilligers van vaccins tegen de agressieve H5N1-vogelgriep zijn niet veelbelovend.
Dat schrijven 24 griepdeskundigen in een donderdag verschenen rapport van de Wereldgezondheidsorganisatie (WHO). Het rapport is het resultaat van een bijeenkomst van de wetenschappers, zes weken geleden in Genève.

De vaccins die nu ontwikkeld worden, bieden volgens de wetenschappers enkel bescherming tegen een deel van de H5N1-griepvirussen. De virussen vallen uiteen in twee hoofdgroepen; vaccins van de ene groep richten weinig uit tegen virussen uit de andere groep. Binnen groep 2 zijn bovendien al zes subgroepen ontstaan. Het aanleggen van voorraden van experimentele vaccins, waartoe onder andere de Verenigde Staten vorig jaar besloten, is volgens de werkgroep ‘mogelijk prematuur’. Nederland slaat geen vaccins op.

Wilde eenden zijn volgens de WHO-werkgroep de belangrijkste verspreiders van het virus, terwijl zwanen (die de afgelopen winter veel dood gevonden werden) wel snel aan de ziekte doodgaan maar weinig bijdragen aan de verspreiding. Verspreiding zou ook versneld worden door contact tussen wilde vogels en pluimvee, waarbij beide groepen elkaar besmetten.

De werkgroep verwacht niet dat de kans op een pandemisch virus in de nabije toekomst vermindert. In Zuidoost-Azië en enkele Afrikaanse landen waren recent uitbraken onder pluimvee. Ook zijn er dit jaar wereldwijd meer menselijke slachtoffers dan in 2005. Dit jaar overleden 74 mensen aan de ziekte, van wie 43 in Indonesië.

In Europa en het Midden-Oosten werden veel vogels ziek in de vorige herfst en winter. Na maart waren er sporadisch uitbraken, en sinds de zomer niet meer.
4 november 2006

[verwijderd] 4 november 2006 14:50

0

Kijktip!

Dinsdag 7 november a.s. om 22.00 uur op BBC 2, uitzending over Bird Flu

www.bbc.co.uk/sn/tvradio/programmes/h...

Tuesday 7 November 2006, 9pm on BBC Two

A simple virus brewed in the belly of a dead bird is set to embark on a global killing spree. The likely culprit is H5N1 - a bird flu virus with the dangerous potential to become humanised and mutate into the next pandemic flu virus.

In a feature-length special, we tell the story of what could happen if a flu pandemic hits. Experts predict the next pandemic will be more disruptive than any disease we've seen before. And they're particularly worried that it will be most deadly for the young and otherwise healthy.

The last flu pandemic in 1918 killed an estimated 50 million people worldwide. Nowadays, with extensive global travel and movement, the virus will be able to spread even more easily. The estimates are that hundreds of millions could be infected and potentially die.

~P

Bijlage:

danicole 5 november 2006 15:09

0

Efforts To Track Bird Flu Hampered By Deficiencies In Data Collection
Main Category: Bird Flu / Avian Flu News
Article Date: 05 Nov 2006 - 6:00am (PST)

The highly pathogenic H5N1 avian influenza has been detected in at least 55 countries in Asia, Europe, and Africa. This often fatal disease is of pressing concern because it can be transmitted from birds to humans, although such transmissions have been rare so far. Unfortunately, according to a Roundtable article in the November 2006 BioScience, the journal of the American Institute of Biological Sciences (AIBS), critical information about incidence of the disease in wild birds--even the species of the infected bird--is often recorded inaccurately or not recorded at all. The deficiencies in data collection, the authors write, "can lead to unwarranted assumptions and conclusions that in turn affect public perceptions, practical control and management measures, and the disposition of resources."

Bird flu is typically studied by veterinarians and virologists. The article's authors, Mai Yasue, Chris J. Feare, Leon Bennun, and Wolfgang Fiedler, made use of the Aiwatch (avian influenza watch) e-mail forum to gather information for their article from sources worldwide. They describe several instances in which the species of an infected wild bird was incorrectly or inadequately recorded--sometimes just as "wild duck," for example--and others in which the bird's sex and age were misidentified. Likewise, reported details of the location and time of discovery of an infected bird often lack specificity, yet they are crucial for a good understanding of the virus's spread. Information about capture and sampling methods and other species in the vicinity of an infected bird has also often been inadequately described. The authors end their article with a plea for greater involvement by ornithologists and ecologists in H5N1 research and monitoring.

[verwijderd] 6 november 2006 16:37

0

California waives ban on mercury flu shots to face shortage

by Emilie Reymond

Get the latest Market Reports on
Sanofi Pasteur
flu vaccine
California

Related News

Sanofi breaks ground in cell culture-based vaccine production
Sanofi Pasteur throws $30m into Canadian vaccine plant
GSK hails breakthrough bird flu vaccine

06/11/2006 - California's Health and Human Services (HHS) has decided to temporarily suspend a ban on mercury-based flu vaccines given to children under three, citing a vaccine shortage caused by production delays.

A law banning a mercury-based preservative called thimerosal from vaccines given to pregnant women and children under three took effect this year, backed by health groups who claim that mercury is linked to autism.
However, only one manufacturer, Sanofi Pasteur, the vaccine unit of French drug giant Sanofi-Aventis, produces the vaccine that complies with California's law, and this year, it started shipping its vaccines three weeks later than usual.

The vaccine manufacturer blamed the delay on difficulty making the vaccine, as flu strains change every year and one of the new strains grew slower than normal, holding up the manufacturing process.

Pressured by physicians from four medical groups, HHS secretary Kim Belshe agreed to a six-week waiver of the ban because she says the health threat from flu outweighs the worries about mercury-free vaccines.

The medical groups said the delays in vaccine production meant that paediatricians have received only partial orders of mercury-free flu vaccines and were having to turn away patients, meaning that many young children could not be protected during the flu season.

However, many doctors have flu shots available with thimerosal that can be used now that the ban is suspended.

Meanwhile, the exemption will also give Sanofi Pasteur time to ship about 500,000 doses of the vaccine without the preservative.

Thimerosal is a mercury-containing preservative used in some vaccines and other products since the 1930s.

According to the Institute of Medicine, no harmful effects have been reported from thimerosal at doses used in vaccines, except for minor reactions like redness and swelling at the injection site, and no scientific evidence links thimerosal to childhood neurological diseases.

However, it is still a very controversial area and in the 1990s, some parents and pediatricians became concerned that thimerosal in children's vaccines might be connected to a nationwide surge in autism rates, which prompted California to vote the state law banning thimerosal from vaccines given to children under three.

But the law can be waived when the paediatric vaccines is in short supply.

Each year, approximately 36,000 people in the US die from influenza and its complications and at least 200,000 are hospitalised.

Young children and the elderly are among those most vulnerable to serious, even fatal complications from influenza, and during the 2004 flu season, more than 150 children in the US died from influenza and many more were hospitalised as a result of complications.

No other vaccine-preventable disease kills more people in this country, according to the HHS.

[verwijderd] 6 november 2006 17:23

0

November 06, 2006 09:10 AM ETGenerex Biotechnology to Begin the First Human Clinical Trial of Avian Influenza Vaccineadvertisement

All Market Wire NewsGenerex Biotechnology Corporation (NASDAQ: GNBT) announced today that it has entered into an agreement with the Lebanese-Canadian Hospital in Beirut, Lebanon to conduct a human clinical trial of the Antigen Express synthetic avian influenza vaccine, representing the first studies to be conducted in man. The study is being undertaken with the approval of the appropriate Lebanese governmental and regulatory bodies. Antigen Express, Inc., a wholly owned subsidiary of Generex, designed the vaccine using its proprietary platform technology and has been conducting pre-clinical studies since 2004. Dr. Alexander Abdelnoor, Department of Microbiology & Immunology, Faculty of Medicine, American University of Beirut, will also be participating as a consultant for the trials.

The vaccine being developed by Antigen Express is based upon simple peptide-synthesis technology and can thus be manufactured rapidly, easily, and at inexpensive cost. This is in sharp contrast to traditional egg-based vaccines that rely on biological systems for vaccine production, making their availability to at-risk populations during a pandemic extremely limited. The preclinical studies conducted with the synthetic vaccine suggest that it may be used with more traditional vaccines to extend their utility as well as to prevent mortality associated with H5N1 infection when used alone.

The Antigen Express vaccine consists of specific fragments of the H5 protein from the H5N1 influenza virus that have been modified to enhance their potency in stimulating CD4+ T helper cells. Flu specific T helper cells have been shown to be essential in the development of a robust, protective immune response against influenza. The methods for enhancing the immune stimulating potency of the fragments were developed by Dr. Robert Humphreys, founder of Antigen Express. In brief, specific fragments of the H5 protein are identified (antigenic epitopes) that have the potential to interact with MHC class II molecules. The ability of CD4+ T helper cells to become stimulated to recognize specific proteins depends upon the presentation of epitopes derived from that protein to CD4+ cells by MHC class II molecules. Based upon an understanding of MHC class II charging by antigenic epitopes, Antigen Express scientists have developed proprietary methods for increasing the vaccine potency of antigenic peptides.

A similar synthetic peptide vaccine designed by the same methods targeting a tumor-associated protein (encoded by HER-2/neu) has been in the clinic for more than a year at the Walter Reed Army Medical Center (WRAMC). That compound has shown good activity in the antigen-specific stimulation of CD4+ T helper cells.

"The trials in Lebanon will complement nicely the studies planned for the US," said Dr. Eric von Hofe, President of Antigen Express. "We know that bird flu is a threat that shows no signs of going away soon. Coupled with the lack of any widely available vaccine, it is paramount to begin testing the synthetic vaccine being developed at Antigen Express as rapidly as possible."

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

[verwijderd] 6 november 2006 22:31

0

Chinese scientists identify deadly gene in H5N1 Mon Nov 6, 5:12 AM ET

HONG KONG (Reuters) - Chinese scientists have identified a gene in the H5N1 bird flu virus which they say is responsible for its virulence in poultry, opening the way for new vaccines.

There are many different strains of H5N1, some of which kill more than half the people they infect, while others do little or no harm.

"We can now understand how this virus becomes lethal and the molecular basis for its pathogenicity," Bu Zhigao at the Harbin Veterinary Research Institute told Reuters.

The Chinese researchers zeroed in on the virulent gene after analyzing two closely related strains of the H5N1 obtained from infected geese in southern Guangdong province in 1996 -- one highly pathogenic in chickens and the other harmless.

Differences between the two strains were located in four genes, they found.

The scientists designed four genetically modified viruses each containing one of the four genes in question and tested them on laboratory chickens.

Only chickens infected with the modified virus containing the highly pathogenic gene died. The other chickens had no signs of disease, the scientists wrote in the November issue of the Journal of Virology.

"Now that we know the special role of the (highly pathogenic) NS1 gene, we can think about developing a vaccine," Bu said, adding that a vaccine which neutralizes the gene known as NS1 could be quickly designed.

"Technically, that can happen very soon, but it is the tests and other procedures that will take a long time."

The scientists are from the Ministry of Agriculture's Animal Influenza Laboratory, the National Key Laboratory of Veterinary Biotechnology, Chinese Academy of Agricultural Sciences, and the Harbin Veterinary Research Institute.

H5N1 remains largely a disease in birds although it has killed over 150 people, mostly in Asia, since 2003. Experts fear that it can spark a pandemic and kill millions of people if it begins to transmit efficiently among humans.

[verwijderd] 7 november 2006 17:17

0

Rising H5N1 'Bird Flu' High-Virulence Sequences Found By Replikins, Ltd.
Main Category: Bird Flu / Avian Flu News
Article Date: 07 Nov 2006 - 0:00am (PST

Replikins, Ltd. has completed a comprehensive quantitative analysis of H5N1 "bird flu" peptide sequences found in humans infected with H5N1 in the past nine years.

The data, obtained from public sources, included 1,455 complete sequences from human specimens. The company has found a continuous and statistically significant increase in the concentration of peptide sub-sequences (previously linked to epidemics) in the H5N1 virus over the past nine years, suggesting a heightened potential for an epidemic outbreak in humans. The replikin concentration in H5N1 has been found to rise steadily, by a factor of 2.5 over the period covered, from 1997 to 2006, from a mean count of 1.9 to the current count of 4.8 units per 100 amino acids (Replikin Count(TM)).

Over the period covered by the study, the mortality rate in human H5N1 cases has in fact also increased by a multiple (2.3 times), from 26 percent in 1997 to 60 percent in 2006, a rise comparable to the increase in the concentration of the replikin sub-sequences.

While a direct causal relationship has not yet been shown, each previous increase in the concentration of replikin protein sub-sequences in flu viruses has been associated with strain-specific influenza epidemics that have occurred in the great pandemics of the last century: in 1918, 1957 and 1968. The same structure of the replikin peptide sub-sequences in influenza now can be traced back from the present to 1917. This conserved structure may be a key to the design of synthetic vaccines whose composition would not have to be changed every year.

Using proprietary technology, Replikins, Ltd. has discovered and defined a group of virus protein sub-sequences - called replikins - which can be used to predict whether a virus is rapidly replicating and whether it is likely to spread.

Replikins, Ltd. has also developed software (FluForecast(R)) which can now detect and count these proteins, which may allow scientists to better predict outbreaks of viral epidemics including H5N1.

Such predictions have been made correctly in advance by the company for the last three "bird flu" (H5N1) outbreaks from 2002 to the present. Prior to this discovery, no protein or other biological phenomenon has been found to correlate directly and quantitatively with viral epidemics. As a result, researchers have had no means to predict if, and what strain of a given viral organism will become a public health threat.

The current concern over when or if there will be an avian flu epidemic in humans has drawn attention to the need for improved measures to help predict, prevent and prepare for emerging health threats.

Dr. Sam Bogoch, Founder of Replikins, Ltd. explained that the finding in human H5N1 virus is significant because, "Combined with the software that analyzes viral strains, we now - for the first time - have an objective quantitative means of determining the threat level of a virus."

"To our knowledge, there is no other product which provides this quantitative predictive information." In explaining how the Replikins proteins were identified, Dr. Bogoch, who also founded the Neurochemistry Laboratory at Harvard Medical School, said, "After discovering the relationship of the structure of the sub-sequence replikin peptides to rapid replication in other infectious organisms, we focused on the influenza virus, because the CDC has epidemiological data available going back nearly 100 years. We discovered that a consistent sub-sequence of peptides increased in concentration in all influenza virus outbreaks."

Replikins, Ltd.
www.replikins.com/

[verwijderd] 8 november 2006 09:53

0

danicole schreef:

www.medicalnewstoday.com/medicalnews....

[verwijderd] 8 november 2006 13:15

0

Novavax's Pandemic Influenza Vaccine Candidates Trigger Robust Immune Response In Pre-Clinical Models
Wednesday November 8, 7:00 am ET
New Data Presented at World Congress on Vaccines, Immunization and Immunotherapy

MONTREAL, Nov. 8 /PRNewswire-FirstCall/ -- Novavax, Inc.'s (Nasdaq: NVAX - News) novel pandemic influenza vaccine candidates triggered a protective immune response in several pre-clinical studies, according to data to be presented for the first time today at the Fifth World Congress on Vaccines, Immunization and Immunotherapy.

Novavax scientists created four vaccine candidates to protect against four different subtypes of human and avian influenza, including H5N1, the strain that global health officials believe could possibly set off a pandemic outbreak. These virus-like particle (VLP) vaccines, which have the three- dimensional structure of the influenza virus but don't contain genetic material, have been tested in three animal models, said Dr. Rick Bright, Novavax Vice President, Global Influenza Programs.

Data show each vaccine candidate triggered an immune response robust enough to protect against infection at very low doses of vaccine. Two of Novavax's vaccine candidates were tested in ferrets, the influenza animal model that is most relevant to humans. These vaccine candidates produced robust immune responses that provided protection against a variety of influenza strains, including strains not included in the vaccines.

Most influenza vaccines are made from proteins. When compared to a single flu protein of a 2002 influenza virus, Novavax's VLP vaccines raised and broadened the ferrets' immune response more than 3.5 times when tested against that virus. In addition, when the immune response was measured against a different influenza strain from 2004, the response generated by Novavax's VLP vaccines was more than eight times higher than that induced by the single flu protein.

"Our data demonstrate the potential for a single vaccine to protect against a range of influenza strains," Dr. Bright said. "This can be a critical factor in a pandemic situation, since a new vaccine would not have to be created every time the virus mutates," Dr. Bright said. "Our goal is to demonstrate in the clinic that our single H5N1 vaccine protects against new mutations of H5N1 viruses." Novavax plans to begin human clinical trials of its pandemic influenza vaccine during the first half of 2007.

While structurally similar to the live influenza virus, Novavax's VLPs do not have the virus's genetic material required for replication or infection. Upon vaccination, these particles attach to cells and trigger a natural immune response that is capable of protecting against influenza. Novavax also has the capability to scale up manufacture of its influenza vaccines rapidly using portable, disposable equipment. This unique manufacturing system does not rely on traditional egg-based methods for vaccine production, which are complex and require cumbersome equipment and many months of preparation.

The data were generated by Novavax and collaborators at the University of Pittsburgh's Center for Vaccine Research, the Southern Research Institute and the U.S. Centers for Disease Control and Prevention.

[verwijderd] 8 november 2006 16:19

0

WHO tells bird flu scientists to stop squabbling
08 Nov 2006 08:53:45 GMT
Source: Reuters
HONG KONG, Nov 8 (Reuters) - The World Health Organisation has urged Chinese and foreign scientists to stop squabbling and share information to figure out how to combat a new H5N1 bird flu virus strain that is spreading unchecked in poultry flocks.
"Instead of having a battle in the media ... we encourage the scientists from the Chinese government and from Hong Kong and elsewhere to sit round a table and go over all these details," said Henk Bekedam, WHO's China representative.
"This is an ideal opportunity to get a better idea what is happening in China and assess strategies that have been effective and develop even more targeted strategies if there is a need."
Chinese officials and scientists rejected a paper published last week by Hong Kong and U.S. scientists who said a new vaccine-resistant "Fujian-like" H5N1 strain had emerged in poultry in China and may spread across Asia and Europe.
In an interview with Chinese media published on Tuesday, two Chinese scientists fired strongly worded rebuttals, saying there was "no scientific basis" for the views and conclusions in the paper. They accused the foreign researchers of "unscientific methods" and said China's vaccination programme was effective.
But they gave no details or data, something that Bekedam says is badly wanting.
"Right or wrong, this goes to a level of details that you have to talk to scientists, people who look at gene sequencing and give us clues as to what is happening," he told Reuters.
"If viruses are substantially different, then it is very important for us to make some re-adjustment in the diagnostics, to consider if we might need to come up with a new vaccine."
H5N1 remains a disease in birds although it has killed over 150 people since late 2003. However, experts fear it could start a pandemic and kill millions if it ever learns to transmit efficiently among people. Research so far into the Fujian strain shows it poses no heightened danger to people.
www.alertnet.org/thenews/newsdesk/HKG...

Chinese bird flu expert to head WHO

Dr Margaret Chan nominated to be WHO Director-General
8 NOVEMBER 2006 | GENEVA -- Dr Margaret Chan of China was nominated today by the Executive Board of the World Health Organization for the post of Director-General. The Director-General is WHO's chief technical and administrative officer.
The nomination will be submitted to the World Health Assembly, which will meet for a one-day special session on Thursday, 9 November to appoint the next Director-General.
The procedures for the current nomination and election process were decided following the sudden death of Dr LEE Jong-wook, WHO Director-General, on 22 May 2006. At its meeting on 23 May, the WHO Executive Board agreed on an "accelerated process" for electing a Director-General.
On Monday the Executive Board, chaired by Dr Fernando Antezana Araníbar of Bolivia, selected a short list of five candidates. Yesterday the Board interviewed the five candidates and today selected Dr Margaret Chan as its nominee.
The WHO Executive Board is composed of 34 Members who are technically qualified in the field of health. The main functions of the Board are to give effect to the decisions and policies of the World Health Assembly, to advise it and generally to facilitate its work.
The countries represented on the current Executive Board are: Afghanistan, Australia, Azerbaijan, Bahrain, Bhutan, Bolivia, Brazil, China, Denmark, Djibouti, El Salvador, Iraq, Jamaica, Japan, Kenya, Latvia, Lesotho, Liberia, Libyan Arab Jamahiriya, Luxembourg, Madagascar, Mali, Mexico, Namibia, Portugal, Romania, Rwanda, Singapore, Slovenia, Sri Lanka, Tonga, Thailand, Turkey and the United States of America.
Dr Anders Nordström, appointed by the Executive Board as Acting Director-General of WHO in May, will continue in this role until a new Director-General takes office.
www.who.int/mediacentre/news/releases...

[verwijderd] 9 november 2006 18:05

0

Uit de Imagine a (HIV) Vaccine-draad:
jan941 - 9 nov 06, 18:00 | Reageer | Quote | Zoek | Aanbevolen: 0

November 09, 2006 08:15:00 AM ETMedImmune Files Investigational New Drug Application for Cell Culture-Based Influenza

GAITHERSBURG, Md., Nov. 9 /PRNewswire-FirstCall/ -- MedImmune, Inc. MEDI announced today that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) to begin human clinical testing of a cell culture-based seasonal influenza vaccine using its proprietary live, attenuated, needle-free influenza vaccine technology. The filing represents a milestone under the terms of a five-year, $170-million contract with the U.S. Department of Health and Human Services (HHS).(1)

MedImmune's currently marketed influenza vaccine, FluMist(R) (Influenza Virus Vaccine Live, Intranasal), is now made using chicken eggs, as are all other U.S.-approved influenza vaccines. Vaccine manufacturers have been using eggs for production for decades; however, using chicken eggs as the production medium limits scalability in manufacturing and increases the potential risk of manufacturing delays or supply shortages. A severe outbreak of avian influenza could kill the flocks used to produce the eggs that would be used for vaccine production. To address these concerns, MedImmune will be applying state-of-the-art cell culture-based manufacturing methods to produce influenza vaccines without the need for chicken eggs. The success of this technology will reduce production times and substantially increase MedImmune's U.S.-based manufacturing capacity to provide influenza vaccine to the U.S. population. After adding the cell culture-based production capability for its influenza vaccine, MedImmune anticipates having the capacity to produce 300 million monovalent bulk doses of a pandemic vaccine annually by 2012.

"MedImmune is pleased to reach this important step in our collaboration with the U.S. government," said James F. Young, president, research and development. "MedImmune's commitment to preparing the country to be protected against influenza illness annually and in the event of a pandemic is stronger than ever, and we are encouraged by the momentum of our research and development efforts."

Under the terms of the contract awarded earlier this year, MedImmune submitted a master product development plan to HHS on November 2, 2006 detailing the company's tactical approach from preclinical testing phases of its cell culture-based vaccine through regulatory licensure. The plan sets forth specific activities related to facility and manufacturing upgrade compliance, as well as vaccine development milestones. The first study of a cell culture- produced seasonal vaccine will characterize safety and immunogenicity in a placebo-controlled trial.

MedImmune is playing an important role in contributing to the nation's armamentarium against both annual seasonal and pandemic influenza. Each year, influenza is responsible for up to 60 million infections,(2) resulting in about 25 million doctors' office visits and hospital stays.(3) Between 1990 and 1999, about 36,000 Americans died from the flu and its complications each year. There is increasing concern that a particularly virulent strain of flu could create a national or worldwide pandemic, leading to high levels of illness, death, social disruption, and economic loss, according to the Centers for Disease Control and Prevention (CDC). MedImmune's research in the influenza field seeks to continue to market and develop products for the very real threats of existing seasonal influenza, while looking into the future at ways to protect Americans against even more dangerous forms of the virus.
www.iex.nl/forum/topic.asp?forum=228&...

danicole 11 november 2006 13:51

1

Novavax's Pandemic Influenza Vaccine Candidates Trigger Robust Immune Response In Pre-Clinical Models

www.medicalnewstoday.com/medicalnews....

(resultaat van: Crucell and Novavax Announce PER.C6(TM) Vaccine Manufacturing Services ??)

H5N1 Bird Flu Virus Is Changing

www.medicalnewstoday.com/medicalnews....

H5N1 Bird Flu Virus Is Changing, FAO And OIE Recommend Increased Surveillance When Vaccinating

www.medicalnewstoday.com/medicalnews....

danicole 11 november 2006 14:01

0

Company Focus
On the front lines of the flu fight (dd 19/10/2005)

"The first time we observe Avian-flu infections unrelated to direct contact with birds or poultry, we should be damn nervous," says Jaap Goudsmit, the chief scientific officer at Crucell (CRXL, news, msgs), a Dutch company in vaccine research.

Human-to-human transmission remains the biggest fear. But will H5N1 make the leap? "I think it is a very high risk because it has happened in the past," says Rahul Singhvi, chief executive of Novavax (NVAX, news, msgs), one company researching bird-flu vaccines. "The virus is continually evolving, and there is no reason it won’t evolve again."

One company that may help is Crucell, which has a technology called PER.C6 that uses human cell lines to develop biopharmaceutical products. Crucell is working with Sanofi-Aventis to produce an Avian flu vaccine using PER.C6 cell lines. Clinical trials are scheduled to start next April. "It is quicker and more reliable because you don’t need eggs," says Goudsmit, the chief science officer at Crucell.

Novavax, a small company based in Malvern, Pa., is exploring innovative ways to produce vaccines. Its system extracts genes from a virus and then uses insect cell lines to rearrange those genes into forms that trigger immune systems against the virus. Novavax says this process has created a vaccine that works against avian flu in rodents. But the company won’t venture a guess on when a vaccine might come to market

moneycentral.msn.com/content/P132582.asp

[verwijderd] 11 november 2006 17:39

0

quote:
danicole schreef:
Company Focus
On the front lines of the flu fight (dd 19/10/2005)

"The first time we observe Avian-flu infections unrelated to direct contact with birds or poultry, we should be damn nervous," says Jaap Goudsmit, the chief scientific officer at Crucell (CRXL, news, msgs), a Dutch company in vaccine research.

Human-to-human transmission remains the biggest fear. But will H5N1 make the leap? "I think it is a very high risk because it has happened in the past," says Rahul Singhvi, chief executive of Novavax (NVAX, news, msgs), one company researching bird-flu vaccines. "The virus is continually evolving, and there is no reason it won’t evolve again."

One company that may help is Crucell, which has a technology called PER.C6 that uses human cell lines to develop biopharmaceutical products. Crucell is working with Sanofi-Aventis to produce an Avian flu vaccine using PER.C6 cell lines. Clinical trials are scheduled to start next April. "It is quicker and more reliable because you don’t need eggs," says Goudsmit, the chief science officer at Crucell.

Novavax, a small company based in Malvern, Pa., is exploring innovative ways to produce vaccines. Its system extracts genes from a virus and then uses insect cell lines to rearrange those genes into forms that trigger immune systems against the virus. Novavax says this process has created a vaccine that works against avian flu in rodents. But the company won’t venture a guess on when a vaccine might come to market

moneycentral.msn.com/content/P132582.asp

www.iex.nl/forum/topic.asp?forum=228&...

Meer uit de doos van Benz:
www.iex.nl/forum/topic.asp?forum=228&...

[verwijderd] 13 november 2006 09:52

0

Vogelgriep bij twee mensen in Indonesië
Uitgegeven op maandag 13 november 2006 om 08:31:37

(Novum/AP) - Indonesië heeft maandag twee nieuwe gevallen van vogelgriep bij mensen gemeld. De patiënten zijn een 35-jarige vrouw en een jongen, die in verschillende voorsteden van de hoofdstad Jakarta wonen. Beiden hebben de ziekte waarschijnlijk opgedaan door contact met ziek pluimvee. Over hun toestand is niets bekendgemaakt.

Het aantal bevestigde gevallen van vogelgriep bij mensen in Indonesië komt hiermee op 74. Sinds 2004 zijn in Indonesië 55 mensen aan vogelgriep gestorven, meer dan in enig ander land.

Melding van: nieuws.nl

[verwijderd] 14 november 2006 07:27

0

RTRS-Amerikanen waarschuwen voor griepmedicijn Tamiflu
WASHINGTON (ANP) - De Amerikaanse autoriteiten waarschuwen
voor psychiatrische afwijkingen door gebruik van het
griepmedicijn Tamiflu. Pati nten die het middel nemen, moeten
goed in de gaten worden gehouden in verband met mogelijk
abnormaal gedrag. De waarschuwing moet voortaan op de
bijsluiter.

De Amerikaanse voedsel- en medicijnenautoriteit FDA reageert
op ruim honderd nieuwe gevallen van ongebruikelijk psychiatrisch
gedrag bij kinderen die Tamiflu hadden genomen, zoals een
delirium of hallucinaties. Het betrof vooral Japanse jongeren.
De FDA benadrukte dat er geen verband tussen het antivirale
medicijn en het gedrag is aangetoond, meldden Amerikaanse media
dinsdag.

De Europese geneesmiddelenautoriteit EMEA kondigde vorig
jaar verscherpt toezicht aan op de mogelijke bijwerkingen van
Tamiflu. EMEA kwam in actie na berichten over zelfmoord van
Japanse jongeren die Tamiflu gebruikten.

((ANP Redactie Economie, email economie(at)anp.nl, +31 20
504 5999))

[verwijderd] 15 november 2006 15:34

0

Chiron zou in oktober in US-trails testen met cell-based H5N1. (Flosz 09-04-2006 11.47).

Flosz, is er al iets bekend. Heb ik een bericht gemist?

redpoint

yinx 15 november 2006 17:18

2

www.novartis-vaccines.com/press-room/...

www.novartis-vaccines.com/press-room/...

danicole 15 november 2006 20:44

0

eFoodSafety.com, Inc. Commences Testing of Influenza A Virus in Conjunction with Bird Flu Virus Testing
Bird Flu Virus Bears Resemblance to Influenza Pandemic That Struck after WWI Killing 50 Million People

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced that the Company has commenced the testing of its Citroxin product on the Influenza A virus in conjunction with its testing of Citroxin against the Bird Flu virus.

The testing is being conducted at Innova Biotechnology Co., Ltd. (http://www.innovabiotechnology.com), one of Thailand’s largest private biotechnology companies specializing in advanced research, development and manufacturing of rapid immunodiagnostic test devices for health care applications. The company is a joint-venture enterprise in Thailand between leading private business and scientists and the National Science and Technology Development Agency (NSTDA), and is supported by the National Center for Genetic Engineering and Biotechnology (BIOTEC) and the National Innovation Agency.

The only recognized treatment currently being used in an attempt to combat the Bird Flu virus is a product designed to treat the Influenza A virus. The treatment’s efficacy is questionable, and it is for this reason that eFoodSafety believes testing of its Citroxin product on the Influenza A virus could easily transpose test results to the Bird Flu virus and allow for a more rapid acceptance of product domestically.

The United Nations Coordinator on the Bird Flu, David Nabarro, has stated that, “The Bird Flu virus will likely remain a significant global threat for animals and humans for the next decade.” He further stated, “The risk of a mutation to cause a pandemic is still very much there.”

The Company periodically updates it shareholders on newsworthy Bird Flu events in an effort to clearly and precisely illustrate the importance of this issue as well as the potential economic impact a solution could have on the Company and its shareholders.

About eFoodSafety.com, Inc.

eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company’s Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) – EPA Reg. No. 82723-1, that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company’s MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn™-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn™ line. The company is also is a distributor for Cinnergen™, a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and Trimmendous™, a weight loss formula focusing on the body’s 24-hour metabolic processes. The company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect™ anti-acne skin care system.

AEX 924,10 -1,03 -0,11% 07 feb


Germany40^	21.738,40	-0,75%
BEL 20	4.337,66	+0,00%
Europe50^	5.319,41	-0,11%
US30^	44.342,20	0,00%
Nasd100^	21.508,40	0,00%
US500^	6.029,92	0,00%
Japan225^	38.404,40	0,00%
Gold spot	2.860,78	0,00%
EUR/USD	1,0327	-0,55%
WTI	70,95	0,00%

THEON INTERNAT	+8,28%
AMG Critical ...	+3,34%
Aperam	+2,47%
UMG	+2,27%
AZERION	+1,83%

EBUSCO HOLDING	-4,60%
ALLFUNDS GROUP	-3,49%
TomTom	-2,57%
BESI	-2,41%
IMCD	-2,38%

Crucell « Terug naar discussie overzicht

Draadje vogelgriep - Deel 2

Meedoen aan de discussie?

Direct naar Forum

Markt vandaag

Aandelenadviezen van IEX.nl

Stijgers

Dalers